Two-drug ART

Dovato

Dovato is a two-drug combination of dolutegravir plus lamivudine in a single tablet.

It is the only two-drug combination for as first-line ART in the 2022 UK guidelines.

It can also be used as a switch combination so long as there is no history of resistance to either of the two drugs.

This combination is approved and recommended for first ART based on results showing it works just as well as using three drugs.

Cabotegravir and rilpivirine long-acting injections:

Long-acting injections are now available in the UK.

They are not yet recommended as a first combination.

Long-acting injections of cabotegravir and rilpivirine are only recommended as a switch option once viral load has been undetectable on oral ART for at least six months.

UK guidelines include other recommendations for when injectable ART can be used. (See pages 113 and 114 of the BHIVA 2023 guidelines).

Juluca

Juluca is an oral fixed dose combination (FDC) of dolutegravir (50 mg) and rilpivirine (25 mg).

It is sometimes used as a switch combination so long as there is no history of drug resistance.

Last updated: 1 November 2024.